Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections

International Journal of Antimicrobial Agents

Volumn 48, Issue 1, 2016, Pages 56-60

  Veve, Michael P ^a,b   Wagner, Jamie L ^a,b   Kenney, Rachel M ^b   Grunwald, Jenny L ^b   Davis, Susan L ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

Antimicrobial stewardship; Ertapenem; ESBL; Extended spectrum lactamase; Fosfomycin; UTI

Indexed keywords

CARBAPENEM; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; ANTIINFECTIVE AGENT; BETA LACTAM; BETA LACTAMASE;

ABDOMINAL PAIN; ADULT; AGED; AMBULATORY CARE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DYSURIA; EMERGENCY WARD; ESCHERICHIA COLI; FEMALE; FEVER; FLANK PAIN; HOSPITAL READMISSION; HUMAN; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGY; OUTPATIENT; PRIORITY JOURNAL; PROPENSITY SCORE; PROSTATITIS; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; URINARY FREQUENCY; URINARY TRACT INFECTION; URINARY URGENCY; URINE CULTURE; ADOLESCENT; CLASSIFICATION; COMPARATIVE STUDY; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ENZYMOLOGY; MIDDLE AGED; SECRETION (PROCESS); URINARY TRACT INFECTIONS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; FOSFOMYCIN; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PATIENT READMISSION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; YOUNG ADULT;

EID: 84971612763     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.04.014     Document Type: Article

References (29)

1. [1] Castanheira, M., Farrell, S.E., Krause, K.M., Jones, R.N., Sader, H.S., Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime–avibactam activity tested against isolates producing the most prevalent β-lactamase group. Antimicrob Agents Chemother 58 (2014), 833–838.
2. [2] Winokur, P.L., Canton, R., Casellas, J.M., Legakis, N., Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 32 (2001), S94–103.
3. [3] Goossens, H., Grabein, B., Prevalence and antimicrobial susceptibility data for extended-spectrum β-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997–2004). Diagn Microbiol Infect Dis 53 (2005), 257–264.
4. [4] Reinert, R.R., Low, D.E., Rossi, F., Zhang, X., Wattal, C., Dowzicky, M.J., Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 60 (2007), 1018–1029.
5. [5] Dhillon, R., Clark, J., ESBLs: a clear and present danger?. Crit Care Res Pract, 2012, 2012, 625170.
6. [6] Paterson, D.L., Bonomo, R.A., Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 18 (2005), 657–686.
7. [7] Falagas, M.E., Karageorgopoulos, D.E., Extended-spectrum β-lactamase-producing organisms. J Hosp Infect 73 (2009), 345–354.
8. [8] Fong, J.J., Rose, L., Radigan, E., Clinical outcomes with ertapenem as a first-line treatment option of infections caused by extended-spectrum β-lactamase producing Gram-negative bacteria. Ann Pharmacother 46 (2012), 347–352.
9. [9] Halilovic, J., Christensen, C.L., Nguyen, H.H., Managing an outpatient parenteral antibiotic therapy team: challenges and solutions. Ther Clin Risk Manag 10 (2014), 459–465.
10. [10] Hussein, K., Sprecher, H., Mashiach, T., Oren, I., Kassis, I., Finkelstein, R., Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol 30 (2009), 666–671.
11. [11] Patel, G., Huprikar, S., Factor, S.H., Jenkins, S.G., Calfee, D.P., Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 29 (2008), 1099–1106.
12. ® package insert. St Louis, MO: Forest Pharmaceuticals Inc http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050717s005lbl.pdf, 2007 accessed 10.05.16.
13. [13] Greenwood, D., Coyle, S., Andrew, J., The trometamol salt of fosfomycin: microbiological evaluation. Eur Urol 13 (1987), 69–75.
14. [14] Reffert, J.L., Smith, W.J., Fosfomycin for the treatment of resistant Gram-negative bacterial infections. Pharmacotherapy 34 (2014), 845–857.
15. [15] Janknegt, R., Hooymans, P.M., Fabius, G.T., Nohlmans-Paulssen, M.K., Machielsen, C., Boogaard-van den Born, J., et al. Urinary concentrations of fosfomycin after a single 3 g dose of fosfomycin to elderly nursing-home patients. Pharm World Sci 16 (1994), 149–153.
16. [16] Popovic, M., Steinort, D., Pillai, S., Joukhadar, C., Fosfomycin: an old, new friend?. Eur J Clin Microbiol Infect Dis 29 (2010), 127–142.
17. [17] Falagas, M.E., Kastoris, A.C., Kapaskelis, A.M., Karageorgopoulos, D.E., Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 10 (2010), 43–50.
18. [18] Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. 2010, CLSI, Wayne, PA Document M100-S20.
19. [19] Gupta, K., Hooton, T.M., Naber, K.G., Wullt, B., Colgan, R., Miller, L.G., et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52 (2011), e103–20.
20. [20] Ducel, G., Fabry, J., Nicolle, L., Girard, R., Perraud, M., Pruss, A., et al. Prevention of hospital-acquired infections: a practical guide. 2nd ed, 2002, World Health Organization, Geneva, Switzerland.
21. [21] Pullukcu, H., Tasbakan, M., Sipahi, O.R., Yamazhan, T., Aydemir, S., Ulusoy, S., Fosfomycin in the treatment of extended spectrum β-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents 29 (2007), 62–65.
22. [22] Rodríguez-Baño, J., Alcala, J.C., Cisneros, J.M., Community infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Arch Intern Med 168 (2008), 1897–1902.
23. [23] Senol, S., Tasbakan, M., Pullukcu, H., Sipahi, O.R., Sipahi, H., Yamazhan, T., Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum β-lactamase-producing Escherichia coli-related complicated lower urinary tract infection. J Chemother 22 (2010), 355–357.
24. [24] Center for Drug Evaluation and Research, Food and Drug Administration, Guidance for industry: non-inferiority clinical trials. http://www.fda.gov/downloads/Drugs/Guidances/UCM202140.pdf, 2010 accessed 05.05.16.
25. [25] Park, D.W., Peck, K.R., Chung, M.H., Lee, J.S., Park, Y.S., Kim, H.Y., et al. Comparison of ertapenem and ceftriaxone therapy for acute pyelonephritis and other complicated urinary tract infections in Korean adults: a randomized, double-blind, multicenter trial. J Korean Med Sci 27 (2012), 476–483.
26. [26] Slama, T.G., Infectious Diseases Society of America. IDSA comments on FDA draft guidance on developing drugs for complicated urinary tract infections (cUTI). 2012.
27. [27] Cassir, N., Rolain, J.M., Brouqui, P., A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front Microbiol, 20, 2014, 551.
28. [28] Dubourg, G., Okdah, L., Le Page, S., Rolain, J.M., Raoult, D., In vitro activity of ‘old antibiotics’ against highly resistant Gram-negative bacteria. Int J Antimicrob Agents 46 (2015), 718–720.
29. [29] Falagas, M.E., Vouloumanou, E.K., Samonis, G., Vardakas, K.Z., Fosfomycin. Clin Microbiol Rev 29 (2016), 321–347.